“…Exciting approaches in development to enhance vaccinemediated protective immunity include a genetically attenuated B. pertussis for intranasal delivery (6), nanoparticle formulations, including purified antigens and novel adjuvant formulations (7), as well as inclusion of additional highly conserved antigens in the current vaccine (8,9). A strong candidate for inclusion in any of these is the adenylate cyclase toxin (ACT), 2 which aids in immune evasion and is produced by three closely related Bordetella species, including B. pertussis, Bordetella parapertussis, and Bordetella bronchiseptica (10,11).…”